Earnings call transcript: Balchem’s Q1 2026 earnings beat expectations
Balchem Corporation (BCPC) reported strong Q1 2026 financial results, with adjusted EPS of $1.33 and revenue of $270.7 million, both exceeding expectations. Despite a pre-market stock decline, the company achieved its 27th consecutive quarter of year-over-year adjusted EBITDA growth and continues to expand its VitaCholine platform and invest in strategic initiatives. Balchem maintains a positive outlook, anticipating continued growth while addressing inflationary pressures and geopolitical risks.
What Balchem (BCPC)'s Q1 2026 Earnings Growth and Buybacks Mean For Shareholders
Balchem Corporation reported increased sales and net income in Q1 2026, alongside a share repurchase, demonstrating strong profitability and a shareholder-focused capital allocation approach. This combination reinforces the earnings per share impact of its operational performance and aligns with its investment narrative as a specialty nutrition and ingredients provider. However, investors are advised to consider potential risks like margin pressure and differing analyst outlooks despite the positive quarterly results.
What Balchem (BCPC)'s Q1 2026 Earnings Growth and Buybacks Mean For Shareholders
Balchem Corporation reported strong Q1 2026 results with year-over-year increases in sales and net income, complemented by share repurchases. This financial performance and capital allocation strategy underscore Balchem's commitment to shareholder returns and reinforce its investment narrative as a specialty nutrition and ingredients provider. Despite positive quarterly numbers, investors are advised to consider potential risks like margin pressure and explore comprehensive analysis, including fair value estimates and future growth forecasts.
Balchem (BCPC) Valuation Check After Q1 Earnings Beat And Ongoing Share Buybacks
Balchem (BCPC) reported strong Q1 2026 results with increased sales and net income, alongside completing a share buyback program. Despite a recent 9.15% drop in stock price over 30 days, its 3-year return remains positive at 27.29%. The article explores whether Balchem, with a fair value estimate of $162, is currently undervalued, considering its investment in a new microencapsulation facility and its P/E ratio of 32.3x which is higher than the industry average.
BCPC SEC Filings - Balchem Corp 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Balchem Corporation (BCPC) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. It aggregates regulatory documents, enhanced with AI-powered summaries, sentiment analysis, and real-time updates. Recent filings cover quarterly earnings, material events, and shareholder meeting results, offering detailed insights into the company's operations and governance.
Balchem (BCPC) Is Down 6.9% After Strong Q1 Earnings And Buyback Completion - What's Changed
Balchem Corporation reported strong Q1 2026 earnings with increased sales of US$270.71 million and net income of US$40.29 million, along with a completed US$25.85 million share buyback program. Despite these positive results, the stock is down 6.9%, which the article attributes to a potential disconnect in investor perception regarding growth catalysts versus tariff pressures and rising fixed costs. The company's future narrative projects significant revenue and earnings growth by 2028, suggesting a potential upside to its fair value.
Balchem (BCPC) Is Down 6.9% After Strong Q1 Earnings And Buyback Completion - What's Changed
Balchem Corporation reported strong Q1 2026 earnings with sales of US$270.71 million and net income of US$40.29 million, along with the completion of a US$25.85 million share buyback program. Despite these positive results, the stock is down 6.9%. The article emphasizes that while these results support the company's growth thesis, investors should also consider potential risks like tariff exposure and rising fixed costs, as well as the impact of ongoing investments on future growth and profitability.
Number of shareholders of Balchem Corp – BX:BL9B
This article provides details about the number of shareholders for Balchem Corp (BX:BL9B). It lists the company's stock symbol on the BX Swiss exchange and includes a table for period value, change, and percentage change. The content highlights the financial data overview for Balchem Corp.
Here’s Why Investors Favored Balchem Corp. (BCPC)
Conestoga Capital Advisors highlighted Balchem Corporation (BCPC) as a significant contributor in its Q1 2026 investor letter, noting the company's steady growth and alignment with consumer trends in a volatile market. Balchem, a specialty chemicals company, reported record quarterly consolidated revenue of $271 million, an 8.1% increase year-over-year. Investors were drawn to BCPC's ability to compound earnings with relatively low volatility.
Assessing Balchem (BCPC) Valuation As Mixed Price Momentum Meets Conflicting Fair Value Estimates
Balchem (BCPC) stock has seen mixed momentum recently, with a small one-day gain but negative performance over the past week, month, and three months. Despite conflicting fair value estimates from analysts and internal models, the company, with a market value of about US$5.2 billion, trades at US$162.10, indicating a potential discount to some intrinsic values. While one narrative suggests it is 10% overvalued at $162 based on analyst targets and earnings multiples, a DCF model points to a higher value, suggesting the current price might be cheaper than analyst assumptions imply.
Balchem Corporation (NASDAQ:BCPC) Q1 2026 Earnings Call Transcript
Balchem Corporation reported record first-quarter 2026 financial results, including strong revenue, adjusted EBITDA, and adjusted EPS, driven by growth across all three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The company highlighted continued market penetration of its specialty nutrients, favorable "better-for-you" trends, and significant progress on strategic initiatives, including research on its VitaCholine nutrient and sustainability goals. Despite facing inflationary pressures and geopolitical uncertainties, Balchem is confident in its ability to maintain growth through effective management and strategic investments.
Balchem (NASDAQ: BCPC) lifts Q1 2026 revenue and maintains solid margins
Balchem Corporation reported strong first-quarter 2026 results, with net sales increasing to $270.7 million and net earnings reaching $40.3 million. The company's gross margin improved to 37.3%, driven by growth across its Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products segments. Balchem also demonstrated solid cash flow from operations and continued its share repurchase program.
Balchem Corporation Reports First Quarter 2026 Financial Results
Balchem Corporation announced strong financial results for the first quarter of 2026, reporting record net sales, adjusted EBITDA, and net earnings across all three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The company achieved net sales of $270.7 million, an 8.1% increase, and adjusted EBITDA of $74.3 million, up 12.1% from the prior year. These results reflect growth driven by higher sales, improved gross margins, and strategic initiatives, despite geopolitical uncertainties.
Balchem (BCPC) Earnings Growth Outpaces 4.8% Revenue Trend Challenging Revenue-Driven Narratives
Balchem (BCPC) reported strong Q1 2026 results, with basic EPS increasing from US$1.03 to US$1.21 and a 20.5% net earnings growth over the past year. This growth significantly outpaces its 4.8% revenue increase, leading to a net profit margin of 14.9%. The article explores how this earning strength challenges traditional revenue-driven narratives and discusses analyst perspectives on the company's valuation and future prospects.
Balchem on Pace for Largest Percent Decrease Since April 2025 -- Data Talk
Balchem Corporation is currently experiencing its most significant percentage decrease since April 2025. This downturn is notable and marks a considerable shift in its stock performance. The article appears to be a data-driven analysis of this financial movement.
Balchem Corporation 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:BCPC) 2026-04-30
This article presents the slide deck published by Balchem Corporation (BCPC) in conjunction with its 2026 Q1 earnings call. The content is provided by SA Transcripts, Seeking Alpha's transcripts team, which publishes thousands of quarterly earnings call transcripts. The purpose is to share transcript-related developments with readers.
Balchem Releases Q1 2026 Financial Results
Balchem Corporation reported mixed financial results for Q1 2026, with earnings of $1.33 per share missing analyst estimates of $1.36 per share. Despite the earnings miss, the company achieved robust revenue growth, reaching $270.7 million, an 8.1% increase from the prior year. This growth was driven by continued demand, particularly in its Human Nutrition and Health division.
Balchem (NASDAQ: BCPC) posts Q1 2026 growth with $270.7M sales
Balchem Corporation reported strong first-quarter 2026 results, with net sales reaching $270.7 million, an 8.1% increase year-over-year, and GAAP net earnings of $40.3 million, up 8.7%. All three business segments—Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products—showed growth in both sales and earnings, with Specialty Products achieving record earnings. The company also generated strong cash flows, paid dividends, and repurchased shares, while maintaining a healthy net-debt leverage ratio.
Balchem Corporation Reports First Quarter 2026 Financial Results
Balchem Corporation reported strong financial results for its first quarter ended March 31, 2026, with record net sales of $270.7 million and significant growth in net earnings and adjusted EBITDA across all three segments. The company highlighted strategic progress, including new clinical research on its VitaCholine® ingredient and the release of its 2025 Sustainability Report. Balchem remains confident in its long-term growth outlook despite geopolitical and global trade uncertainties.
Balchem Corp. Reports Increase In Q1 Income
Balchem Corp. (BCPC) announced an increase in its first-quarter income, with net income rising to $40.29 million, or $1.25 per share, compared to $37.05 million, or $1.13 per share, in the prior year. Excluding certain items, adjusted earnings for the period were $42.99 million, or $1.33 per share. The company also reported an 8.1% increase in revenue, reaching $270.71 million from $250.52 million a year ago.
Balchem Corporation Reports First Quarter 2026 Financial Results
Balchem Corporation reported strong first-quarter 2026 financial results with record net sales of $270.7 million, adjusted EBITDA of $74.3 million, and net earnings of $40.3 million. The company saw sales and earnings growth across all three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. Balchem also highlighted recent clinical research on its VitaCholine® ingredient and the release of its 2025 Sustainability Report.
Balchem posts record quarter as all 3 business units grow
Balchem Corporation reported record Q1 2026 financial results, with net sales of $270.7 million, GAAP net earnings of $40.3 million, and adjusted EBITDA of $74.3 million. All three of its business segments—Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products—showed growth. Despite strong operational performance, the stock experienced a negative market reaction, declining 6.76% on the day the news was published.
Vanguard reports 5.24% stake in Balchem (BCPC) — 1.68M shares
Vanguard Capital Management has reported a 5.24% beneficial ownership in Balchem Corp, amounting to 1,680,971 shares, as of March 31, 2026. This Schedule 13G filing indicates sole dispositive power over all these shares and sole voting power over 248,883 shares. The filing is a passive disclosure, signaling sizable institutional ownership but no active control or transaction intent.
Balchem earnings up next: Can growth offset margin pressure?
Balchem Corporation is set to release its first-quarter earnings, with analysts anticipating a 10.6% increase in EPS and 6.1% revenue growth year-over-year, despite a sequential decline in EPS from the previous quarter. Investors will closely watch the performance of its Human Nutrition & Health segment, margin trends amidst rising costs and investments, and management's outlook for 2026. The company, which has a "Buy" rating and an implied 13% upside, faces the challenge of sustaining growth while managing operational complexities in a moderating economic environment.
Balchem Corp. Experiences Revision in Its Stock Evaluation Amid Strong Market Performance
Balchem Corp., a small-cap FMCG player, has adjusted its stock valuation, now featuring a P/E ratio of 35 and a price-to-book value of 4.30. The company reported a significant dividend yield of 49.07% and a year-to-date return of 13.32%, outperforming the S&P 500. These strong financial metrics highlight Balchem's competitive position within its industry compared to its peers.
[SCHEDULE 13G] BALCHEM CORP Passive Investment Disclosure (>5%)
Vanguard Portfolio Management has filed a Schedule 13G disclosing a passive investment in Balchem Corp, holding 2,221,969 shares of Common Stock, which represents 6.93% of the class as of March 31, 2026. The filing indicates Vanguard's sole dispositive power over these shares and sole voting power over 28,552 shares. This disclosure signals a significant institutional stake without implying activist intent, as is typical for 13G filings.
Balchem Corporation: The Formulation-Embedded Compounder That Has Not Missed a Year
Balchem Corporation, a microencapsulation specialist with a beta of 0.37, has been profitable every year on record and has increased its dividend for 17 consecutive years. The company's unique "formulation dependency" model creates high switching costs for customers, particularly within its Human Nutrition and Health segment, which drives its strong operating margins and consistent free cash flow growth. Despite a premium valuation compared to peers, the article argues Balchem's differentiated economics justify the price for long-term investors seeking dependable compounding.
Balchem (BCPC) Valuation Check After Recent Share Price Strength And Long Term Returns
Balchem (BCPC) has seen recent share price strength but is currently considered overvalued by Simply Wall St, trading at US$175.17 against a fair value of $162. While there's optimism around its growth potential and analyst targets are higher, concerns about underutilized capacity and impact on gross margins persist. The article encourages investors to conduct their own analysis given the mixed outlook.
Balchem Corporation Releases 2025 Sustainability Report
Balchem Corporation has published its 2025 Sustainability Report, detailing significant progress in environmental and social initiatives. The company surpassed its 2030 greenhouse gas emissions reduction target and is on track to reduce water withdrawal, while also celebrating its fifth anniversary as a signatory to the UN Global Compact. Balchem continues to focus on employee safety and product quality, with approximately 75% of its revenue supporting key UN Sustainable Development Goals.
Balchem beat its 2030 emissions goal in 2025, cutting 31% from 2020
Balchem Corporation announced in its 2025 Sustainability Report that it surpassed its 2030 goal for greenhouse gas emissions, achieving a 31% absolute reduction in Scope 1 and 2 emissions from its 2020 baseline. The company also reported a 16% reduction in water withdrawal and stated that approximately 75% of its revenue supports specific UN Sustainable Development Goals. Balchem introduced external limited assurance for certain emissions data, emphasizing its commitment to transparent sustainability reporting.
Balchem Corporation Releases 2025 Sustainability Report
Balchem Corporation has released its 2025 Sustainability Report, highlighting significant progress in its environmental and social initiatives. The report details the company's achievement of surpassing its 2030 greenhouse gas emissions reduction target and its ongoing commitment to reducing water withdrawal. Balchem also noted its alignment with the UN Global Compact and its contributions to several UN Sustainable Development Goals.
Balchem Corporation Announces Quarterly Conference Call for First Quarter 2026 Financial Results on April 30, 2026
Balchem Corporation (NASDAQ: BCPC) announced a conference call to discuss its first-quarter 2026 financial results on Thursday, April 30, 2026, at 11:00 AM ET. The call will be hosted by Ted Harris and Martin Bengtsson, with results published before the market opens. Investors and the public can join via dial-in or live webcast, with a replay available for one year.
How many employees work at Balchem?
Balchem Corp. currently has 1,194 employees, reflecting a 3.3% year-over-year growth rate as of December 2025. The company specializes in providing solutions and products across ARC Specialty Products, Food, Pharma and Nutrition, and Animal Nutrition and Health segments. Revelio Labs data indicates a steady increase in employee headcount over the past few years, alongside fluctuations in active job postings.
Balchem Corporation Announces Quarterly Conference Call for First Quarter 2026 Financial Results on April 30, 2026
Balchem Corporation announced a conference call to discuss its first-quarter 2026 financial results, scheduled for Thursday, April 30, 2026, at 11:00 AM ET. The results will be released before the market opens on the same day. Investors can join the call via dial-in or a live webcast, with replay available afterward.
Balchem Corporation Announces Quarterly Conference Call for First Quarter 2026 Financial Results on April 30, 2026
Balchem Corporation announced a conference call to discuss its first-quarter 2026 financial results, which will be held on Thursday, April 30, 2026, at 11:00 AM Eastern Time. The call will be hosted by Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO. First quarter results will be published before the market opens on April 30, 2026, and a live webcast will be available for investors and the public.
Balchem to post first-quarter results before markets open April 30
Balchem (NASDAQ: BCPC) announced it will host a conference call on April 30, 2026, at 11:00 AM ET to discuss its first-quarter 2026 financial results. The results and financial exhibits will be released prior to market open on the same day and will be available on the company's website. Chairman, President, and CEO Ted Harris, along with CFO Martin Bengtsson, will host the call.
Zinc Methionine Chelates Market Forecast Report 2025-2033 Featuring Alltech, Balchem, Titan Biotech, UNO VETCHEM, Zinpro, Chaitanya Biologicals, Chengdu Chelation Biology, JH, Novus, Priya
The Zinc Methionine Chelates Market is projected to grow from US$ 15.64 million in 2025 to US$ 26.51 million by 2033, exhibiting a CAGR of 6.82%. This growth is primarily fueled by the increasing demand for bioavailable mineral supplements in livestock feed, driven by the need to prevent zinc deficiency and enhance animal nutrition and feed efficiency across agricultural, pharmaceutical, and nutraceutical sectors. Key growth drivers include the shift towards sustainable animal nutrition, advancements in chelation technology, and supportive government policies, with major players like Zinpro Corporation and Novus International leading the market.
BCPC (Balchem) Gross Property, Plant and Equipment : $581 Mil (As of Dec. 2025)
Balchem (NAS:BCPC) reported its Gross Property, Plant and Equipment at $581 million as of December 2025, an increase from previous quarters and years. The company currently has a GF Score of 95/100 and a GF Value of $171.07, indicating it is "Fairly Valued" despite trading slightly above this estimate. Investors are advised to consider multiple financial metrics and warning signs in addition to PPE for a complete analysis.
Balchem Corp. Experiences Revision in Its Stock Evaluation Amid Competitive FMCG Landscape
Balchem Corp., a small-cap FMCG player, has adjusted its valuation, now showing a P/E ratio of 35 and a price-to-book value of 4.30. The company boasts a strong dividend yield of 49.07% and competitive returns on capital and equity. These metrics position Balchem favorably against peers like J. M. Smucker Co., Conagra Brands, Inc., and Ingredion, Inc., highlighting its competitive standing in the FMCG sector.
BCPC Financials: Revenue Breakdown, Margins & Competitor Comparison
The article provides a financial overview of Balchem Corp (BCPC), detailing its revenue breakdown, profitability margins, and a comparison with competitors LW and POST. BCPC primarily generates revenue from Product Sales and demonstrates strong profitability with a gross margin of 35.62%, an operating margin of 19.84%, and a net margin of 14.88%. The analysis highlights the company's significant market capitalization within the Specialty Chemicals industry and its competitive efficiency.
Balchem Corp. Experiences Revision in Its Stock Evaluation Amid Competitive FMCG Landscape
Balchem Corp. has adjusted its stock valuation, now showing a P/E ratio of 35 and a price-to-book value of 4.30. The company boasts a significant dividend yield of 49.07% and strong return metrics, positioning it favorably against competitors like The J. M. Smucker Co. and Conagra Brands within the FMCG sector. Its valuation metrics indicate a competitive edge, especially when compared to both lower and higher P/E ratios among industry peers.
Balchem (BCPC) CAO details stock, option and restricted share positions
Balchem Corp's Chief Accounting Officer, Erin Leigh Gilson, filed an initial ownership report detailing her equity positions. The report includes common stock, shares held indirectly through a 401(k) plan, and various employee stock options with exercise prices ranging from $74.57 to $143.43, expiring between 2028 and 2034. Additionally, she holds restricted stock awards that vest over three years.
Balchem Corp (BCPC) Stock Price Quote Today & Current Price Chart
This article provides a stock price quote today and current price chart for Balchem Corp (BCPC). It suggests using Smart Investment App from Capital.com for online trading.
Assessing Balchem (BCPC) Valuation After Recent Share Price Gains And Multi Year Returns
Balchem (BCPC) has seen recent share price gains but a month-long decline, while still showing stronger multi-year returns. Valued at $170.44, it's considered 5.2% overvalued by analysts with a fair value estimate of $162, partly due to concerns about potentially underutilized capacity and its impact on earnings growth. However, international expansion and new clinical data could challenge this cautious outlook.
Clinical study suggests Balchem's K2VITAL supports post-exercise neuromuscular signalling in older adults
A new clinical study indicates that Balchem's K2VITAL, a vitamin K2 MK-7 supplement, can improve neuromuscular signaling in adults aged 65 and over following resistance exercise. While no significant effects were seen across all participants, subgroup analysis of older adults showed enhanced nerve-muscle communication, suggesting K2VITAL may support healthy aging. Balchem highlights K2VITAL's established benefits in cardiovascular and bone health and its potential for further research in healthy aging.
BALCHEM Graham Number: $31.69 — 380% Above Median
Balchem Corp (NAS:BCPC) has a Graham Number of $31.69 as of December 2025, which is 380% above its 10-year median of 6.60. GuruFocus rates BCPC as "Fairly Valued" with a GF Score™ of 94/100, though it notes two warning signs and a Price to Graham Number ratio of 5.27, placing it worse than 91.13% of companies in the Chemicals industry. The Graham Number is a conservative valuation metric that combines asset and earnings power, but does not account for growth.
Balchem (FRA:BL9B) NonCurrent Deferred Revenue : €0.0 Mil (As of Dec. 2025)
This article reports that Balchem (FRA:BL9B) has a NonCurrent Deferred Revenue of €0.0 Mil as of December 2025. GuruFocus rates Balchem with a GF Score of 89/100 and considers it fairly valued, with a GF Value of €149.44 against a current price of €143.20. The article defines Non-Current Deferred Revenue as the non-current portion of deferred revenue where revenue has not yet been recognized and is not expected to be recognized within the next twelve months.
Vanguard (NYSE: BCPC) reports zero beneficial ownership after realignment
The Vanguard Group has filed an amended Schedule 13G/A, reporting zero beneficial ownership of Balchem Corp (BCPC) common stock. This change is a result of an internal realignment effective January 12, 2026, where certain Vanguard subsidiaries will now report their holdings separately. The filing confirms Vanguard holds no voting or dispositive power over Balchem stock as of the amendment date.
BCPC SEC Filings - Balchem Corp 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Balchem Corporation (BCPC) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading information. It details recent Form 8-K filings and Form 4 insider transactions, many of which involve tax-related share withholdings by executives. The platform also offers AI-powered summaries to simplify complex sections of these regulatory documents for investors and traders.
BCPC SEC Filings - Balchem Corp 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Balchem Corporation (BCPC) SEC filings, including 10-K, 10-Q, and 8-K forms, offering detailed insights into the company's operations and financial performance. It highlights recent filings such as a Form 3 for an officer with zero beneficial ownership, Q3 2025 earnings showing increased net sales and net income, and shareholder approval for board elections and executive compensation. The platform also offers AI-powered summaries to help investors understand complex regulatory documents and track insider transactions.
